Literature DB >> 10490715

Absence of linkage and linkage disequilibrium to chromosome 15q11-q13 markers in 139 multiplex families with autism.

B Salmon1, J Hallmayer, T Rogers, L Kalaydjieva, P B Petersen, P Nicholas, C Pingree, W McMahon, D Spiker, L Lotspeich, H Kraemer, P McCague, S Dimiceli, N Nouri, T Pitts, J Yang, D Hinds, R M Myers, N Risch.   

Abstract

Chromosomal region 15q11-q13 has been implicated to harbor a susceptibility gene or genes underlying autism. Evidence has been derived from the existence of cytogenetic anomalies in this region associated with autism, and the report of linkage in a modest collection of multiplex families. Most recently, linkage disequilibrium with the marker GABRB3-155CA2 in the candidate locus GABRB3, located in this region, has been reported. We searched for linkage using eight microsatellite markers located in this region of chromosome 15 in 147 affected sib-pairs from 139 multiplex autism families. We also tested for linkage disequilibrium in the same set of families with the same markers. We found no evidence for excess allele sharing (linkage) for the markers in this region. Also, we found no evidence of linkage disequilibrium, including for the locus GABRB3-155CA2. Thus, it appears that the role of this region of chromosome 15 is minor, at best, in the majority of individuals with autism.

Entities:  

Mesh:

Year:  1999        PMID: 10490715

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  23 in total

Review 1.  The pathophysiology and treatment of autism.

Authors:  D J Posey; C J McDougle
Journal:  Curr Psychiatry Rep       Date:  2001-04       Impact factor: 5.285

2.  Epigenetic overlap in autism-spectrum neurodevelopmental disorders: MECP2 deficiency causes reduced expression of UBE3A and GABRB3.

Authors:  Rodney C Samaco; Amber Hogart; Janine M LaSalle
Journal:  Hum Mol Genet       Date:  2004-12-22       Impact factor: 6.150

3.  No evidence for significant association between GABA receptor genes in chromosome 15q11-q13 and autism in a Japanese population.

Authors:  Mamoru Tochigi; Chieko Kato; Shinko Koishi; Yuki Kawakubo; Kenji Yamamoto; Hideo Matsumoto; Ohiko Hashimoto; Soo-Yung Kim; Keiichiro Watanabe; Yukiko Kano; Eiji Nanba; Nobumasa Kato; Tsukasa Sasaki
Journal:  J Hum Genet       Date:  2007-10-24       Impact factor: 3.172

Review 4.  Emerging drugs for the treatment of symptoms associated with autism spectrum disorders.

Authors:  Logan K Wink; Martin H Plawecki; Craig A Erickson; Kimberly A Stigler; Christopher J McDougle
Journal:  Expert Opin Emerg Drugs       Date:  2010-09       Impact factor: 4.191

Review 5.  Early pharmacological treatment of autism: a rationale for developmental treatment.

Authors:  Terrence C Bethea; Linmarie Sikich
Journal:  Biol Psychiatry       Date:  2007-02-15       Impact factor: 13.382

Review 6.  Autism spectrum and obsessive-compulsive disorders: OC behaviors, phenotypes and genetics.

Authors:  Suma Jacob; Angeli Landeros-Weisenberger; James F Leckman
Journal:  Autism Res       Date:  2009-12       Impact factor: 5.216

7.  Letting a typical mouse judge whether mouse social interactions are atypical.

Authors:  Charisma R Shah; Carl Gunnar Forsberg; Jing-Qiong Kang; Jeremy Veenstra-VanderWeele
Journal:  Autism Res       Date:  2013-02-21       Impact factor: 5.216

Review 8.  Autism: in search of susceptibility genes.

Authors:  Janine A Lamb; Jeremy R Parr; Anthony J Bailey; Anthony P Monaco
Journal:  Neuromolecular Med       Date:  2002       Impact factor: 3.843

Review 9.  Meta-Analysis of the Association between GABA Receptor Polymorphisms and Autism Spectrum Disorder (ASD).

Authors:  Manijeh Mahdavi; Majid Kheirollahi; Roya Riahi; Fariborz Khorvash; Mehdi Khorrami; Maryam Mirsafaie
Journal:  J Mol Neurosci       Date:  2018-05-03       Impact factor: 3.444

Review 10.  Decreased left perisylvian GABA concentration in children with autism and unaffected siblings.

Authors:  Donald C Rojas; Debra Singel; Sarah Steinmetz; Susan Hepburn; Mark S Brown
Journal:  Neuroimage       Date:  2013-01-28       Impact factor: 6.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.